Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication

INTRODUCTION: In October 2010, the US Food and Drug Administration (FDA) issued a safety communication regarding the risks of atypical fractures of the femur, with bisphosphonates drugs. This study evaluated the impact of the bisphosphonates FDA safety communication on the utilization of osteoporosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Balkhi, Bander, Seoane-Vazquez, Enrique, Rodriguez-Monguio, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111194/
https://www.ncbi.nlm.nih.gov/pubmed/30166922
http://dx.doi.org/10.1016/j.jsps.2017.12.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111194/
https://www.ncbi.nlm.nih.gov/pubmed/30166922
http://dx.doi.org/10.1016/j.jsps.2017.12.005

Ejemplares similares